Your browser doesn't support javascript.
loading
UDP-6-glucose dehydrogenase in hormonally responsive breast cancers.
Price, Meghan J; Nguyen, Annee D; Haines, Corinne; Baëta, César D; Byemerwa, Jovita; Murkajee, Debarati; Artham, Sandeep; Kumar, Vardhman; Lavau, Catherine; Wardell, Suzanne; Varghese, Shyni; Goodwin, C Rory.
Afiliação
  • Price MJ; Department of Neurosurgery, Duke University Medical Center, University School of Medicine, Durham, NC, USA.
  • Nguyen AD; Department of Medicine, John Hopkins Hospital, 1800 Orleans St, Baltimore, MD 21287, USA.
  • Haines C; Department of Neurosurgery, Duke University Medical Center, University School of Medicine, Durham, NC, USA.
  • Baëta CD; Department of Molecular Genetics, Ohio State University, 1060 Carmack Road, Columbus, OH 43210, USA.
  • Byemerwa J; Department of Neurosurgery, Duke University Medical Center, University School of Medicine, Durham, NC, USA.
  • Murkajee D; Center for Population Health Sciences, Stanford University, 1701 Page Mill Road, Palo Alto, CA 94304, USA.
  • Artham S; Department of Pharmacology and Cancer Biology, Duke University Medical Center, University School of Medicine, Durham, NC, USA.
  • Kumar V; Department of Pharmacology and Cancer Biology, Duke University Medical Center, University School of Medicine, Durham, NC, USA.
  • Lavau C; Department of Pharmacology and Cancer Biology, Duke University Medical Center, University School of Medicine, Durham, NC, USA.
  • Wardell S; Department of Biomedical Engineering, Duke University Medical Center, Durham, NC, USA.
  • Varghese S; Department of Neurosurgery, Duke University Medical Center, University School of Medicine, Durham, NC, USA.
  • Goodwin CR; Department of Pharmacology and Cancer Biology, Duke University Medical Center, University School of Medicine, Durham, NC, USA.
bioRxiv ; 2024 Mar 21.
Article em En | MEDLINE | ID: mdl-38562874
ABSTRACT
Survival for metastatic breast cancer is low and thus, continued efforts to treat and prevent metastatic progression are critical. Estrogen is shown to promote aggressive phenotypes in multiple cancer models irrespective of estrogen receptor (ER) status. Similarly, UDP-Glucose 6-dehydrogenase (UGDH) a ubiquitously expressed enzyme involved in extracellular matrix precursors, as well as hormone processing increases migratory and invasive properties in cancer models. While the role of UGDH in cellular migration is defined, how it intersects with and impacts hormone signaling pathways associated with tumor progression in metastatic breast cancer has not been explored. Here we demonstrate that UGDH knockdown blunts estrogen-induced tumorigenic phenotypes (migration and colony formation) in ER+ and ER- breast cancer in vitro. Knockdown of UGDH also inhibits extravasation of ER- breast cancer ex vivo, primary tumor growth and animal survival in vivo in both ER+ and ER- breast cancer. We also use single cell RNA-sequencing to demonstrate that our findings translate to a human breast cancer clinical specimen. Our findings support the role of estrogen and UGDH in breast cancer progression provide a foundation for future studies to evaluate the role of UGDH in therapeutic resistance to improve outcomes and survival for breast cancer patients.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article